Cathie Wood lost her conviction and dumped the stock. Can Illumina get back on track?
News & Analysis: Illumina
It'll cover a lot of ground in the next 14 years.
It just might be.
The advice of Warren Buffett's biggest influencers supports these solid picks.
Nearly everything went right for the genomic sequencing pioneer.
ILMN earnings call for the period ending March 31, 2021.
The administration's focus on the Affordable Care Act, access to healthcare, and research may accelerate growth for these three stocks.
Sometimes the most carefully laid plans hit unforeseen snags.
The gene sequencing giant has a couple of key challenges going forward.
This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.